T-1-PMPA, a potent EGFR inhibitor, demonstrates apoptotic properties and effectively inhibits EGFR WT and EGFR 790m, with IC50 values of 86 nM and 561.73 nM, respectively [1].

EGFR WT:86 nM, EGFR T790M:561.73 nM

T-1-PMPA (0.312-10 μM; 24 h) significantly suppresses the proliferation of HepG2 and MCF7 malignant cell lines, with IC50 values of 3.51 μM and 4.13 μM respectively [1]. In HepG2 cells, T-1-PMPA increases the proportion of early apoptotic cells from 0.77% to 29.17%, late apoptotic cells from 0.17% to 8.81%, and the overall apoptotic cell population from 3.05% to 42.03%. Additionally, the percentage of necrotic cells rises to 4.05% compared to 2.21% in control cells. qRT-PCR analysis reveals a significant increase in levels of caspase-3 and caspase-9, further supporting its apoptotic effect. T-1-PMPA regulates TNFα and IL2 levels to 74% and 50% accordingly [1]. Cell Viability Assay [1] Cell Line: HepG2 and MCF7 malignant cell lines Concentration: 0.312 μM, 0.625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM Incubation Time: 24 h Result: Displayed noteworthy inhibition of the proliferation of HepG2 and MCF7 malignant cell lines.